ENVB

Enveric Biosciences Inc

ENVB, USA

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. The company was founded in 2020 and is headquartered in Cambridge, Massachusetts.

https://www.enveric.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ENVB
stock
ENVB

Enveric Biosciences Secures $3.1M Through Warrant Exercise TipRanks

Read more →
ENVB
stock
ENVB

Enveric Biosciences raises $3.1 million through warrant exercise By Investing.com Investing.com South Africa

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$10

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bearish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.86

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-54.21 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-42.95 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.26

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 14.39% of the total shares of Enveric Biosciences Inc

1.

AdvisorShares Psychedelics ETF

(6.2742%)

since

2025/08/29

2.

AdvisorShares Investments, LLC

(3.1938%)

since

2025/06/30

3.

Renaissance Technologies Corp

(1.1401%)

since

2025/06/30

4.

Geode Capital Management, LLC

(0.8675%)

since

2025/06/30

5.

UBS Group AG

(0.8422%)

since

2025/06/30

6.

Virtu Financial LLC

(0.6394%)

since

2025/06/30

7.

Morgan Stanley - Brokerage Accounts

(0.4011%)

since

2025/06/30

8.

Fidelity Extended Market Index

(0.3852%)

since

2025/07/31

9.

Fidelity Nasdaq Composite Index

(0.3362%)

since

2025/07/31

10.

Fidelity Series Total Market Index

(0.1433%)

since

2025/07/31

11.

Tower Research Capital LLC

(0.0911%)

since

2025/06/30

12.

Vanguard Institutional Extnd Mkt Idx Tr

(0.0257%)

since

2025/07/31

13.

BlackRock Inc

(0.0185%)

since

2025/06/30

14.

SBI Securities Co Ltd

(0.0185%)

since

2025/06/30

15.

Spartan Extended Market Index Pool F

(0.0027%)

since

2025/07/31

16.

NT Ext Equity Mkt Idx Fd - NL

(0.001%)

since

2025/06/30

17.

Barclays PLC

(0.0009%)

since

2025/03/31

18.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0008%)

since

2025/06/30

19.

Bank of America Corp

(0.0007%)

since

2025/06/30

20.

State St US Extended Mkt Indx NL Cl C

(0.0007%)

since

2025/08/31

21.

Northern Trust Extended Eq Market Idx

(0.0005%)

since

2025/06/30

22.

NT Ext Equity Mkt Idx Fd - L

(0.0005%)

since

2025/06/30

23.

SSgA U.S. Total Market Index Strategy

(0.0003%)

since

2025/03/31

24.

Wells Fargo & Co

(0.0001%)

since

2025/06/30

25.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0001%)

since

2024/12/31

26.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0001%)

since

2025/06/30

27.

Group One Trading, LP

(0%)

since

2025/06/30

28.

JONES FINANCIAL COMPANIES LLLP

(0%)

since

2025/06/30

29.

FMR Inc

(0%)

since

2025/06/30

30.

Citadel Advisors Llc

(0%)

since

2025/06/30

31.

Headlands Technologies LLC

(0%)

since

2025/06/30

33.

HRT FINANCIAL LLC

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-10.81

EPS Estimate

-0.35

EPS Difference

-10.46

Surprise Percent

-2988.5714%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(6.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Possible Net-Net(6)
Quality
Low Quality Business(3)
Value
Undervalued(7)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.